---
title: "Metastatic Colon Cancer"
slug: "metastatic-colon-cancer"
date: "2023-08-23"
enableToc: false
tags:
  - building
---

> [!info]
>
> ğŸŒ± ä¾†è‡ª: [[colorectal cancer]]

# Metastatic Colon Cancer

> [[ESMO guidelines of Metastatic Colon Cancer]] ó°’—

- Chemotherapy for advanced and metastatic disease
- Definitions:
  - [[FOLFOX]]:
    - Infusional [[Fluorouracil]] 5-FU/LV [[FULV]] +
      - AEs_5FU: ğŸ’©ğŸ‘„ğŸ¤®ğŸ©¸ğŸ¤ğŸ«€ğŸ‘ï¸ğŸ–ï¸ğŸ¦¶ğŸ˜‡ğŸŒ
    - [[Oxaliplatin]]
  - [[FOLFIRI]]: Infusional 5-FU/LV + [[Irinotecan]];
  - [[FOLFOXIRI]]: Infusional 5-FU/LV + OX + irinotecan;
  - CAPEOX: [[Capecitabine]]  Diarrhea, HFS,  (5FU pro, 3 steps to convert to 5FU, same aE) + OX
    - Xeloda 500mg/tab 1200mg/BSA
- 1st line: [[FOLFOX]] (JCO 2004;22:23) Â± [[Bevacizumab]] (JCO 2008;26:2013); [[CAPEOX]]; FOLFIRI (JCO 2004;22:229) Â± Bev (JCO 2007;25:4779); FOLFOXIRI Â± Bev ([[TRIBE]], NEJM 2014;371:1609)
- [[anti-VEGF]]: è¡€æ “å‡ºè¡€è›‹ç™½å°¿ã€è¡“å¾Œå‚·å£é«˜è¡€å£“
- For pts w/ L-sided CRC & wt [[RAS]]/[[BRAF]]: FOLFOX or FOLFIRI Â± [[cetuximab]]/[[panitumumab]] ([[CRYSTAL]], NEJM 2009;360:1408; [[PRIME]], JCO 2010;28:4697)
  - R-sided CRC: C,A,T
  - [[cetuximab vs bevacizumab]]:
    - [[FIRE-3]] 28.7 month
    - [[CALGB-SWOG 80405]] 30 month
    - [[PARADIGM]] 37.9 vs 34.3
- If pts not appropriate for intense Rx: Infusional 5-FU/LV; Cape
- 2nd line:
  - FOLFIRI or irinotecan for pts who received prior FOLFOX;
  - FOLFOX/CAPEOX for pts w/ prior FOLFIRI;
    - [[GERCOR]]
  - FOLFOX/CAPEOX, or FOLFIRI for prior 5-FU/LV or Cape;
  - all regimens Â±
    - Bev/ziv-[[aflibercept]]/[[ramucirumab]]
      - Bev 11.2 vs 9.8: [[ML18147]]
      - ziv-aflib 4mg/kg 13.5 vs 12.6: [[VELOUR]] agranulocytosis
      - ramu 13.6 vs 11.7: [[RAISE]]
    - (note that Bev is â†’ preferred over ziv-[[aflibercept]]/[[ramucirumab]] because of tox &/or cost);
  - irinotecan-based regimens Â±;
  - cetuximab/panitumumab if not previously used
    - phase III, continued use of bevacizumab plus standard second-line chemotherapy in patients with metastatic colorectal cancer progressing after standard first-line bevacizumab-based treatment.
  - [[BRiTE]] BRiTE observational cohort study

---
- 3rd line: Irinotecan Â± panitumumab/cetuximab ([[BOND]], NEJM 2004;351:337) or single-agent panitumumab/cetuximab, or single-agent [[regorafenib]] or [[TAS-102]]; overall benefits of regorafenib or TAS-102 are modest w/ significant s/e
  - [[CORRECT]] 160mg/day for three week in 28d cycle â™»ï¸
  - [[RECOURSE]] 35/BSA 1-5 8-15 in 28d cycle â™»ï¸
- 1st line for MSI-H/dMMR: Pembrolizumab ([[KEY line for MSI-JM 2020;383:2207) or nivolumab Â± ipilimumab ([[CHECKMATE 142]], Lancet Oncol 2017;18:1182)
- Later line for [[BRAF V600E]] mut: [[encorafenib]] + cetuximab/panitumumab ([[BEACON]], NEJM 2019;381:1632); addition of binimetinib did not improve OS or ORR
- Later line for HER2 amplified & RAS/BRAF wildtype: Trastuzumab + pertuzumab; trastuzumab + lapatinib; trastuzumab deruxtecan
- For FOLFOX, OX should be discontinued after first 3 mos of Rx till progression to reduce risk of severe neurotoxicity. Can be resumed at â†£ or after progression (OPTIMOX1, JCO 2006;24:394)
- Do not use concurrent anti-EGFR + anti-VEGF Rx (CAIRO2, NEJM 2009;360:563)
- Do not use anti-EGFR Rx in RAS/BRAF mut or any R sided CRC (JCO 2016;34(suppl, abstr 3504, 3505, 3506; JAMA Oncol 2017;3:211)
- For pts progressing on anti-EGFR, use of anti-EGFR is â†’ not rec in subsequent lines
## [[UpToDate Links of Metastatic Colon Cancer|UpToDate Links]] ó°’–
---

- 2024-07-14: TOS 2024 ASCO
- [[evolution_of_treatment_in_mcrc_in_2024.md|Evolution of treatment in mCRC in 2024]]

